GLP-1 receptor agonists may be considered when additional treatment goals include weight reduction, improved glycemic control, chronic kidney disease risk reduction, or lowering atherosclerotic cardiovascular risk, particularly in patients with obesity or established Atherosclerotic Cardiovascular Disease (ASCVD) [7, 16, 47]
Zafardoust et al., 2023a
Following GF-MKD intervention, plasma levels of L-leucine and coumarin decreased by approximately 46% and 60%, respectively, while betaine levels showed a modest increase
While it can significantly improve energy, libido, mood, and overall quality of life, like any medical treatment, it may carry some side effectsone of which is polycythemia
Zweier and Talukder, 2006)